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Interleukin-1 receptor family members (ILRs) and toll-like receptors (TLRs) are charac-
terized by the presence of a conserved intracellular domain and the toll-IL-1resistance 
(TIR) domain and are key players in immunity and inflammation. ILR and TLR signaling 
is tightly regulated at different levels. All cell types of the innate immune system express 
ILRs and TLRs. In addition, IL-1 family members are emerging as key players in the 
differentiation and function of innate and adaptive lymphoid cells. IL-1R8, also known as 
TIR8 or SIGIRR, is a fringe member of the ILR family and acts as a negative regulator of 
ILR and TLR signaling, which dampens ILR- and TLR-mediated cell activation. IL-1R8 is 
a component of the receptor recognizing human IL-37. Here, we summarize our current 
understanding of the structure and function of IL-1R8, focusing on its role in different 
pathological conditions, ranging from infectious and sterile inflammation to autoimmunity 
and cancer-related inflammation.
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iNTRODUCTiON
Interleukin-1 receptor family members (ILRs) and toll-like receptors (TLRs) are members of a super-
family characterized by the presence of a common intracellular signaling domain, called toll-IL-1 
resistance (TIR) domain, and Ig-like domains or leucine-rich repeats in their extracellular part (1) 
(Figure 1). ILRs and TLRs are phylogenetically conserved receptors responsible for the initiation 
and amplification of events leading to inflammation and innate and adaptive immune responses. 
TLRs work as sensors for exogenous infectious agents and host tissue injury, recognizing specific 
pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns 
(DAMPs). Ten TLRs have been identified to date in humans and 12 in the mouse. The ILR subfamily 
is a growing family of receptors and accessory proteins (AcP) for the cytokines of the IL-1 family. The 
nomenclature of ILRs has recently been revised (2) and will be used here: IL-1R1 (IL-1RI), IL-1R2 
(IL-1RII), IL-1R3 (IL-1RAcP), IL-1R4 (ST2), IL-1R5 (IL-18Rα), IL-1R6 (IL-1Rrp2, IL-36R), IL-1R7 
(IL-18Rβ), IL-1R8 (also known as TIR8 or SIGIRR), IL-1R9 (TIGIRR-2), and IL-1R10 (TIGIRR-1). 
The IL-1 system includes molecules with agonist activity (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, 
and IL-36γ), three receptor antagonists (IL-1Ra, IL-36Ra, and IL-38), and an anti-inflammatory 
cytokine (IL-37) (Figure 1).
Upon ligand binding, TLRs and ILRs dimerize through their TIR domains, inducing the recruit-
ment of TIR domain-containing adapter proteins, in particular MyD88, MAL, TRIF, TRAM, and 
SARM, which couple to downstream protein kinases [e.g., IL-1R-associated kinases (IRAKs) and 
tumor necrosis factor receptor-associated factor 6 (TRAF6)]. The signal leads to the activation of key 
transcription factors associated with inflammatory and immune responses, such as nuclear factor-κB 
FiGURe 1 | The iL-1 receptor (iLRs) and toll-like receptor (TLRs) superfamily. Ligands, receptors, accessory proteins, and regulators are shown. Ligands of 
the ILR family include IL-1α, IL-1β, IL-38, IL-33, IL-36α, IL-36β, IL-36γ, and IL-18. Microbial compounds (LPS, CpG, poly IC, flagellin, and others), β-amyloid, and 
danger signals are ligands for TLRs. IL-1R, IL-33R, IL-36R, and IL-18R complexes transduce positive signals. IL-R2, sIL-1R1, IL-1Ra, IL-36Ra IL-18BP, and IL-1R8 
are negative regulators acting at different levels. IL-37 is an anti-inflammatory cytokine, which signal is dependent on the formation of a tripartite complex (IL-37/
IL-1R5/IL-1R8). IL-1R3 is an accessory protein, which activity is necessary for IL-R1, IL-1R2, IL-1R4, and IL-1R6 function. IL-1R8, IL-1R9, and IL-1R10 are still 
orphan receptors.
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(NFκB), activator protein-1 (AP-1), c-Jun N-terminal kinase 
(JNK), p38 mitogen-associated protein kinase, extracellular sig-
nal-regulated kinases (ERKs), mitogen-activated protein kinases 
(MAPKs), and members of the interferon (IFN)-regulatory factor 
(IRF) (3–5).
IL-1 family and TLR signaling are a crucial network that 
covers a wide spectrum of functions in several tissues and cell 
types, ranging from tissue homeostasis regulation to protective 
responses against infections and modulation of inflammation. 
Given the huge capacity of ILR and TLR triggering to drive 
inflammatory responses, the strict regulation of this system 
plays a significant role in both physiological and pathological 
conditions.
Both ILR and TLR functional activations are modulated by 
several and diverse mechanisms. Among these, IL-1R2 exerts 
regulatory functions acting as decoy receptor for IL-1, dominant-
negative molecule, and scavenger (6, 7). In addition, it is also 
present in the cytoplasm where it binds pro-IL-1α and pro-IL-1β, 
preventing their cleavage and activation (8). IL-1R8, also known as 
TIR8 or SIGIRR, whose function will be detailed below, is a fringe 
member of the family that lacks conventional signaling capacities 
and behaves as a negative regulator of the family, acting intra-
cellularly. Available information suggests that IL-1R8 interferes 
with the association of TIR-containing adaptor molecules to the 
receptor complex, thus dampening the signaling pathway leading 
to signal transduction (9, 10). In addition, IL-1R8 is a component 
of the receptor recognizing the anti-inflammatory cytokine IL-37 
(11). IL-37 is an anti-inflammatory cytokine that acts as a natural 
brake of inflammation, signaling through IL-1R5/IL-18Rα and 
IL-1R8 was recently described as a coreceptor, required for the 
formation of the tripartite complex IL-37–IL-1R5/IL-18Rα–
IL-1R8 (11). IL-18BP is an extracellular protein that binds IL-18, 
preventing its interaction with the receptor IL-1R5/IL-18R, and 
thus neutralizing its activity (12–14). IL-1Ra and IL-36Ra are 
receptor antagonists that bind IL-1R1 and IL-1R6, respectively 
(5, 15–18).
IRAK-M and MyD88s are intracellular signaling molecules 
that negatively regulate ILR and TLR pathways (19, 20). Finally, 
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specific miRNAs (miR-155, miR-21, miR-146a, miR-132, miR-9, 
and miR-147) target ILR and TLR signaling proteins (21–23). 
The abundance of these regulatory mechanisms underlines the 
relevance of the negative regulation of both ILRs and TLRs, 
which if uncontrolled, may activate detrimental inflammation 
and cause tissue damage. For instance, local and systemic inflam-
mation induced by IL-1 underlay a broad list of diseases, ranging 
from rheumatic diseases and autoinflammatory syndromes 
to cardiovascular diseases, type 2 diabetes, and infections and 
sepsis, and targeting of IL-1 has relevant therapeutic implications 
(24–27).
Here, we will review our current understanding of the 
structure and function of the negative regulator IL-1R8 (TIR8/
SIGIRR), focusing on its relevance in different inflammatory 
or immune-mediated pathological disorders and emphasizing 
recent discoveries.
iL-1R8 (TiR8/SiGiRR) GeNe AND PROTeiN
IL-1R8 was identified by our group and reported as TIR8 in 1998 
(Accession number: AF113795), and in parallel by John Sims’ 
group in 1999 and reported as SIGIRR (28). IL-1R8 is localized 
on human chromosome 11, band p15.5, and is composed of 10 
exons spanning about 11,700 bp (28). It is therefore not part of the 
IL-1R family cluster, which is located in humans on chromosome 
2. The murine gene is localized on chromosome 7, band F4, and 
encompasses nine exons spanning about 4000  bp. The human 
protein is 410 amino acids long and displays unique features 
compared with other ILRs. It is composed of a single extracellular 
Ig domain, in contrast with the other family members which have 
three, a transmembrane domain, a cytoplasmic TIR domain, and 
an unusually long tail (95 residues), which is missing in other TIR 
domain-containing receptors. The IL-1R8 TIR domain lacks two 
conserved residues (Ser447 and Tyr536), which are replaced by 
Cys222 and Leu305 suggesting unconventional signaling. IL-1R6 
and IL-1R3 display a similar amino acid substitution in their TIR 
domain, but the functional relevance of this replacement has not 
been addressed yet (28, 29).
IL-1R8 sequence is highly conserved among vertebrates, from 
chicken to human in terms of sequence and pattern of expression 
(30). Human and murine protein sequences are 82% identical and 
share 23% overall identity with IL-1R1. In teleost fish, the receptor 
DIGIRR, which has two Ig-like domains in its extracellular region 
and an Arg–Tyr-mutated TIR domain, exerts regulatory activities 
in vitro, negatively modulating LPS, and IL-1β-dependent NFκB 
activation, therefore resembling a “transitional” form between 
the signaling molecule IL-1R1 and the negative regulator IL-1R8 
(31).
IL-1R8 has five potential N-glycosylation sites in the extracel-
lular domain in humans and four in the mouse and is extensively 
N- and O-glycosylated. Zhao et al. recently showed that loss of 
N-linked glycosylation was associated with an inactive isoform 
of IL-1R8, generated by alternative splicing in colon cancer cells. 
Moreover, loss of complex glycan modifications was sufficient to 
suppress IL-1R8 activity in vivo, highlighting that posttranscrip-
tional modifications are required for the functional activity of 
IL-1R8 (32).
IL-1R8 is widely expressed in several epithelial tissues, in 
particular by epithelial cells of the kidney, digestive tract, liver, 
lung, and in lymphoid organs. Among leukocytes, it is expressed 
by monocytes, B and T lymphocytes, dendritic cells, and NK cells 
(28, 33). Little is known about the regulation of IL-1R8 expression 
and the stimuli and pathways involved. In general, both IL-1R8 
mRNA and protein expression are reduced in inflammatory 
conditions. IL-1R8 was downmodulated in ulcerative colitis in 
humans and colitis in the mouse, intestinal bacterial infections, 
and exposure to flagellin (34, 35). The expression of IL-1R8 (and 
other anti-inflammatory molecules) was reduced in leukocytes of 
psoriatic arthritis patients and, together with TLR4, it was reduced 
in asymptomatic bacteriuria patients (36, 37). Nanthakumar 
et al. showed that IL-1R8 level was decreased in intestinal cells 
of necrotizing enterocolitis patients compared with fetal human 
enterocytes, whereas pro-inflammatory proteins were expressed 
at high levels, in line with the exacerbated inflammatory response 
of the immature intestine (38). In the mouse, acute lung infection 
by Pseudomonas aeruginosa caused IL-1R8 mRNA downregula-
tion in the lung and in neutrophils (39). IL-1R8 transcript was 
also reduced upon intestinal infection by Toxoplasma gondii 
(40). In a model of pyelonephritis induced by Escherichia coli, 
it was shown that renal IL-1R8 mRNA was downregulated in 
the early phase of infection and it started to return to basal level 
24 h postinfection (41). Moreover, in vitro experiments in human 
bladder epithelial cells (BECs) demonstrated that IL-1R8 mRNA 
and protein expression were downregulated upon stimulation 
with LPS (42). Finally, colon tumorigenesis was shown to be asso-
ciated with a lower expression level of IL-1R8 on the intestinal cell 
surface compared with the healthy counterpart. This was due to 
a mechanism of alternative splicing that caused the generation of 
an inactive mutant form of IL-1R8 that will be further discussed 
below (32).
Concerning the mechanism of IL-1R8 downregulation, Kadota 
et  al. showed that LPS treatment reduced the binding between 
SP1, a zinc finger protein, and the proximal promoter of IL-1R8 
(34). SP1 would normally directly interact with IL-1R8 promoter 
and favor gene transcription, but in presence of LPS the bind-
ing was inhibited and IL-1R8 expression transiently decreased 
in epithelial cells. Recently, the role of SP1 in the regulation of 
IL-1R8 mRNA expression was also confirmed in human primary 
monocytes and neutrophils. The inhibition of SP1 binding to 
IL-1R8 promoter induced by LPS was due to the activation of 
p38, which is downstream of TLR4. Indeed, treatment of both 
monocytes and neutrophils with a p38 inhibitor (SB203580) 
abolished the LPS-induced downregulation of IL-1R8 mRNA 
(43). Conversely, sepsis and sterile systemic inflammation have 
been associated with higher level of IL-1R8 expression by mono-
cytes compared with homeostatic conditions, which correlated 
with reduced TNFα and enhanced IL-10 production in response 
to LPS and Pam3CysSK4 (44).
IL-1R8 is differentially expressed in polarized T lymphocytes. 
Murine Th2 cells displayed higher levels of IL-1R8 compared 
with Th1 or naive T cells (45). In P. aeruginosa-infected mice, 
IL-1R8 was upregulated by the neuropeptide vasoactive intestinal 
peptide (VIP) in a cAMP-independent manner in the cornea, 
in macrophages, and in Langerhans cells (46). The probiotic 
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microorganism Lactobacillus jensenii was found to upregulate 
IL-1R8, via TLR2 in porcine Payer’s patch antigen-presenting cells, 
and to favor the expression of IL-10 and TGF-β, thus inducing 
tolerogenic properties (47). Finally, in murine Payer’s patch DCs, 
but not splenic DCs, LPS was shown to induce the upregulation of 
IL-1R8, Tollip, and IL-1R4. This could be a potential mechanism 
used by Payer’s patch DCs to modulate the inflammation driven 
by TLR signaling (48).
Recently, Costello et  al. proposed a mechanism involved in 
IL-1R8 regulation in the context of neuroinflammation. Amyloid 
β treatment increased the expression of TLR2 and decreased 
the expression of IL-1R8 in microglia. Interestingly, TLR2 neu-
tralization led to an increase of IL-1R8 mRNA in microglia and 
hippocampal tissue (49). The transcription factor peroxisome 
proliferator-activated receptor (PPAR)γ is a key anti-inflammatory 
mediator that regulates Aβ responses in the brain. Binding sites 
for the transcription factor PPARγ were identified in the IL-1R8 
gene and treatment with the PPARγ inhibitor (GW9662) reduced 
the anti-TLR2-mediated IL-1R8 upregulation, supporting the 
involvement of PPARγ in the modulation of IL-1R8 expression. 
The PI3K/Akt pathway was also involved in the regulation of 
IL-1R8, since PI3K inhibitor (LY294002) abolished the effect of 
TLR2 neutralization. The expression of IL-1R8 and TLR2 is there-
fore inversely correlated and IL-1R8 upregulation mediated by 
TLR2 neutralization may be a compensation mechanism adopted 
to limit the deleterious effect of Aβ (49).
iL-1R8-MeDiATeD ANTi-iNFLAMMATORY 
ACTiviTY OF iL-37
IL-1R8 was considered an orphan receptor, lacking a specific 
ligand. IL-37 has been recently demonstrated to bind IL-1R8 and 
to generate the tripartite complex IL-37–IL-1R5/IL-18Rα–IL-1R8 
(11) (Figure 2). IL-37 is an anti-inflammatory cytokine that damp-
ens the inflammatory response triggered by TLRs and cytokines 
in peripheral blood mononuclear cells (PBMCs), in macrophages 
and epithelial cells, and IL-37-transgenic mice (IL-37tg mice) are 
protected in different inflammatory pathological conditions (50). 
Recently, advanced imaging analysis revealed a rapid interaction 
of IL-37 with both IL-1R5/IL-18Rα and IL-1R8 in human PBMCs 
and bone marrow-derived macrophages (BMDMs) of IL-37tg 
mice upon stimulation with LPS (11). In particular, following a 
pro-inflammatory stimulus, the tripartite complex IL-37–IL-1R5/
IL-18Rα–IL-1R8 was formed on the cell membrane of PBMCs 
and cell lines (RAW, HEK293, and A549). IL-1R8 and IL-1R5/
IL-18Rα were both required to support the anti-inflammatory 
activity of IL-37 in PBMCs, THP-1 macrophages, and A549 
epithelial cells. Indeed, silencing of IL-1R8 or IL-1R5/IL-18Rα or 
both in these cell types impaired the IL-37-mediated reduction 
of inflammatory cytokines (e.g., IL-β and TNF), upon stimula-
tion with LPS. Finally, proteomic and transcriptomic analysis 
demonstrated that the IL-37–IL-1R5/IL-18Rα–IL-1R8 complex 
triggered multiple signaling events leading to anti-inflammatory 
responses, such as inhibition of MAPK, NFκB, mTOR, TAK1, 
and Fyn and activation of STAT3, Mer, PTEN, and p62(dok). 
Thus, IL-1R8 acts as a coreceptor for IL-1R5/IL-18Rα upon IL-37 
binding, and it is required for the anti-inflammatory activity of 
IL-37 (11, 51) (Figure  2). This mechanism is relevant in  vivo, 
since IL-1R8 deficiency abolished the protection of IL-37tg mice 
against endotoxin challenge or the protective role of IL-37 in a 
model of non-resolving Aspergillus fumigatus infection and pul-
monary damage (11, 52). Moreover, in a model of OVA-induced 
asthma, IL-37-driven anti-inflammatory effects were abolished in 
mice lacking either IL-1R5/IL-18Rα or IL-1R8 (53).
IL-37-overexpressing mice showed improved response to 
insulin and increased glucose tolerance and were protected from 
obesity. In addition, in adipocytes and macrophages IL-37 acti-
vated AMPK (54). Since IL-37–IL-1R8 signaling inhibited mTOR 
signaling, whereas AMPK, STAT6, and transcription factors of 
the Foxo family were activated (11), these results indicate that the 
IL-37–IL-1R8 axis is also involved in regulating inflammation-
dependent modification of cell metabolism, favoring a pseudo-
starvational state in macrophages and DCs.
Thus, these results demonstrate that IL-1R8 is part of the 
receptor complex of the anti-inflammatory cytokine IL-37 and 
mediates an anti-inflammatory signaling activation.
ReGULATiON OF iLR AND TLR 
SiGNALiNG BY iL-1R8
IL-1R8 exerts its regulatory activity by inhibiting NFκB and JNK 
activation induced by TIR-containing ILRs or TLRs upon ligand 
binding, but not by other receptors such as TNF receptors. In 
particular, IL-1R8 was shown to tune the activation of IL-1R1, 
IL-1R5/IL-18Rα, IL-1R4/ST2, TLR4, TLR7, TLR9, TLR3, and 
TLR1/2 (29, 45, 55–57) (Figure 3).
The knowledge about the mechanism of inhibition exerted 
by IL-1R8 is still fragmentary. Upon stimulation with IL-1, the 
IL-1R8 extracellular domain was shown to block the dimeriza-
tion between IL-1R1 and IL-1R3/IL-1RAcP, and the intracellular 
TIR domain was shown to bind the TIR-containing adaptor 
protein MyD88 and downstream signaling molecules (IRAK and 
TRAF6), thus modulating IL-1 signaling (55, 57). Similarly, the 
targeting of IL-1R4/ST2 was shown to be dependent on both the 
extracellular immunoglobulin and TIR domains (45). In contrast, 
only the TIR domain was necessary for the inhibition of TLR4 
signaling, as demonstrated by mutagenesis studies (55, 57). 
Indeed, a nonsense mutation (Q111*) and a frameshift mutation 
(P2fs) cause the generation of a truncated form of IL-1R8, which 
lose inhibitory activity (55, 57, 58). A computational approach 
revealed that IL-1R8 targeting of TLR4 and TLR7 signaling was 
dependent on IL-1R8 intracellular TIR domain and in particular 
on the BB-loop, which is shared by all TIR domain-containing 
proteins. The model proposed showed that IL-1R8 binds through 
its BB-loop region to TLR4 and TLR7 interfering with the dimeri-
zation site and replaces a MyD88 monomer, thus disturbing 
MyD88 homodimerization (59). Recent computational studies 
that predict the three-dimensional structures of the TLR family 
proteins suggested that IL-1R8 does not block the formation of 
the Myd88-dependent signalosome, but it inhibits NFκB activa-
tion by preventing the translocation of the signalosome from 
the receptor (58). This strategy would be similar to that used by 
FiGURe 2 | iL-37–iL-1R5–iL-1R8 tripartite complex. IL-37 anti-inflammatory activity is exerted through the formation of a membrane bound tripartite complex 
composed of IL-37, IL-1R5, and IL-1R8.
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IRAK-M, which blocks the dissociation of the myddosome from 
the receptor (19).
Moreover, it was demonstrated that IL-1R8 could potentially 
interact with all TIR domain-containing proteins in the TLR 
pathway, preventing the dimerization of Mal, TRAM, and TRIF, 
and inhibiting signalosome formation. However, the BB-loop of 
IL-1R8 is not involved in the interaction with Mal and TRAM. 
Thus, in addition to MyD88-dependent pathway, IL-1R8 can 
inhibit TRIF-dependent signaling. Indeed, IL-1R8 was shown 
to target TRIF-dependent TLR3 signaling, probably by blocking 
TRAM homodimerization and TLR4–TRAM and TRIF–TRAM 
interactions (10, 58, 60). One of the clinically observed oncogenic 
mutations of IL-1R8 (L282M) is located on the IL-1R8–Mal and 
IL-1R8–TRIF interaction sites and abolishes the interaction with 
TRIF. These results indicate that the BB-loop of IL-1R8 is relevant 
in the interaction with TLRs, but not necessarily with other TIR-
containing molecules (58).
c-Jun N-terminal kinase and mTOR phosphorylation were 
enhanced in IL-1R8-deficient Th17 cells. IL-1R8 is therefore 
crucial in the modulation of metabolism, differentiation, expan-
sion, and effector functions of Th17 cells (61). IL-1R8 was also 
demonstrated to target mTOR phosphorylation driven by IL-1 
or TLR agonists derived from commensal flora in intestinal epi-
thelial cells (IECs) (62). IL-1R8 therefore emerges as a regulator 
of the cell cycle, playing a crucial role in homeostatic conditions 
(Figure 3).
The interaction between IL-1R8 and other receptors of the 
family is still poorly defined and sometimes contradictory. This 
could be due to posttranscriptional modifications in different cell 
types that can affect its functions.
Thus, these results indicate that IL-1R8 interferes with the 
formation of TIR domain signalosome, prevents the dimeriza-
tion of receptors, AcP, and adaptor molecules, and blocks signal 
transduction.
FiGURe 3 | Negative regulation exerted by iL-1R8. IL-1R8 is composed of a single extracellular domain, a transmembrane domain, a cytoplasmic TIR domain, 
and an unusually long tail (95 residues). The IL-1R8 TIR domain lacks two conserved residues (Ser447 and Tyr536), which are replaced by Cys222 and Leu305 
suggesting unconventional signaling. IL-1R8 acts as a negative regulator of ILR and TLR signaling, inhibiting TIR-containing receptors and adaptor proteins, and 
thus blocking Akt, JNK, MAPKs, TAK1, and consequently mTOR and NFκB activation.
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ROLe OF iL-1R8 iN iNFeCTiON-DRiveN 
iNFLAMMATiON
IL-1R8 emerged as a non-redundant molecule in infectious 
conditions, playing a key role in the regulation of TLR and ILR 
responses to pathogens by dampening inflammation and tissue 
damage (Figure 4).
In Mycobacterium tuberculosis infection, IL-1R8-deficient 
mice displayed higher mortality compared with the control group, 
even if no difference in tissue bacterial load in the lung, liver, or 
spleen was observed. The increased susceptibility was dependent 
on the exacerbated systemic inflammatory response. Indeed, 
IL-R8-deficient mice presented an overwhelming inflammatory 
response, which is characterized by enhanced macrophage and 
neutrophil lung infiltration and increased systemic levels of 
inflammatory cytokines. The in vivo depletion of crucial inflam-
matory mediators (IL-1 and TNFα) in M. tuberculosis infection 
significantly prolonged the survival of IL-1R8-deficient mice 
(63). In a model of keratitis induced by P. aeruginosa, IL-1R8 was 
involved in the regulation of IL-1R1 and TLR4 signaling in T cells 
and dampening Th1 response, thus preventing tissue damage and 
promoting resistance to infection (64). Similarly, in acute lung 
infections caused by P. aeruginosa, IL-1R8-deficient mice showed 
increased susceptibility to the pathogen, in terms of mortality and 
bacterial load, and increased production of pro-inflammatory 
cytokines, both locally and systemically. The enhanced suscepti-
bility was dependent on the deregulation of IL-1 signaling, since 
IL-1R1 deficiency abolished the phenotype observed in IL-1R8-
deficient mice. IL-1R8 therefore emerged as a non-redundant 
regulator of IL-1 mediated control of P. aeruginosa infection (39).
In C. albicans and A. fumigatus infections, the absence of 
IL-1R8 led to increased susceptibility to mucosal and dis-
seminated or lung infections (65). IL-1R8-deficient mice showed 
increased mortality and fungal burden, enhanced activation 
FiGURe 4 | Roles of iL-1R8 in pathology. IL-1R8-deficient mice have demonstrated that IL-1R8 acts a key modulator of acute and chronic inflammation in 
several pathological contexts. For instance, IL-1R8 plays a non-redundant role in models of bacterial infections, fungal infections, autoimmune diseases, allergy, 
asthma, renal inflammation, brain inflammation, intestinal inflammation, and cancer (colorectal cancer and CLL).
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of IL-1 signaling and Th17 cell response, and reduced Treg 
 activation. This correlated with higher levels of IL-12, IL-23, IL-6, 
IFN-γ, and IL-17 and reduced levels of IL-10. IL-1R8 was demon-
strated to be a regulator of Th17 cells and IL-17A production by 
γδ T cells and a modulator of T cell polarization. The phenotype 
observed in IL-1R8-deficient mice could be due to a deregulated 
Th17 response, which is dependent on the uncontrolled IL-1 
signaling. Indeed, in vitro experiments demonstrated that IL-17 
production by CD4+ T cells, primed with Candida-pulsed DCs, 
was reduced by the treatment with IL-1β- and IL-23-blocking 
antibodies (65).
The role of IL-1R8 is therefore attributable to the negative 
regulation of IL-1 signaling in P. aeruginosa, C. albicans, and M. 
tuberculosis infections, since IL-1 neutralization was sufficient to 
abolish the phenotype in IL-1R8-deficient mice.
Moreover, IL-1R8-deficient mice on a BALB/c background 
showed enhanced mortality, upon endotoxin challenge (55). 
In line with this, IL-1R8 overexpression in lung epithelial cells 
reduced the inflammatory response and improved the survival of 
BALB/c mice in a model of LPS-dependent acute lung injury (66). 
Since IL-1R8-deficient mice on a C57BL/6 × 129/Sv background 
revealed no difference in terms of LPS reaction, compared with 
controls, it has been hypothesized that IL-1R8-mediated regula-
tion of LPS response may depend on the background of mice 
(56).
The relevance of these data in the mouse was supported by a 
case-population study design in Vietnam, showing that 3 SNPs 
(rs10902158, rs7105848, rs7111432) in IL-1R8 gene correlated 
with the development of both pulmonary tuberculosis and 
tuberculous meningitis. Moreover, coinheritance of these SNPs 
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with previously identified polymorphisms in TLR2 and TIRAP 
was associated with enhanced risk of susceptibility (67).
The protective role of IL-1R8 in the infections mentioned above 
is due to the regulation of ILR and TLR signaling that potentially 
cause detrimental inflammation and tissue damage. However, in 
a model of experimental urinary tract infection (UTI) induced by 
uropathogenic E. coli, IL-1R8-deficient mice displayed reduced 
renal bacteria outgrowth and diminished renal dysfunction 
UTI. IL-1R8 also modulated the recruitment of immune cells in 
the kidney, since a more sustained renal neutrophil influx was 
observed in the early phase of infection in IL-1R8-deficient mice. 
This is possibly due to the activity of IL-1R8 in dampening E. 
coli induced activation of tubular epithelial cells. Indeed, in vitro 
stimulation of IL-1R8-deficient tubular epithelial cells with LPS 
or heat-killed E. coli resulted in increased production of TNFα 
and chemokines (CXCL1, CCL2, and CCL3) and a mild increased 
expression of the adhesion molecule ICAM-1. Finally, IL-1R8 
mRNA transcript was reduced in kidneys during the early phase 
of E. coli induced pyelonephritis (41). A recent in  vitro study 
demonstrated that IL-1R8 regulates the responsiveness to LPS 
in a human BEC line, and, in line with previous studies, IL-1R8 
mRNA and protein expression were downregulated upon stimu-
lation with LPS (42). IL-1R8 silencing in BECs caused increased 
LPS-induced IL-6 and IL-8 production and this correlated 
with enhanced phosphorylation rate of JNK, p38, and ERK1/2. 
Finally, IL-1R8 siRNA transfected cells developed an impaired 
LPS tolerance, suggesting that IL-1R8 is involved in this process. 
Overall, these findings highlighted the importance of IL-1R8 in 
the negative regulation of urinary tract and renal response to 
bacterial infections (42).
Similar to what was observed in UTI, during pneumonia and 
sepsis induced by Streptococcus pneumoniae in the mouse, IL-1R8 
deficiency was associated with delayed mortality, reduced bacte-
rial load in the lungs, and reduced dissemination of the infection 
(68). Increased interstitial and perivascular inflammation was 
observed in IL-1R8-deficient lungs mice in the early phase of 
infection. Thus, IL-1R8 suppressed the protective antibacterial 
immune response in S. pneumoniae induced pneumonia (68).
Murine models of Citrobacter rodentium infection resemble 
human intestinal infections driven by enteric bacterial patho-
gens, such as enterohemorrhagic E. coli (EHEC) and Salmonella 
typhimurium. Upon C. rodentium infection, IL-1R8 deficiency 
correlated with accelerated IEC proliferation and enhanced pro-
inflammatory and antimicrobial response. However, IL-1R8 was 
shown to be protective in this model, in terms of weight loss, intes-
tinal damage, colitis score, and intestinal bacterial burden. IL-1R8 
protective function was dependent on IL-1R1–MyD88 signaling, 
but not on TLR2 or TLR4 pathways, indicating that IL-1R1 may 
be the key receptor targeted by IL-1R8 in this context. Infected 
IL-1R8-deficient mice underwent a more rapid and dramatic loss 
of commensal flora, compared with controls. In infected mice, the 
microbiota depletion was directly dependent on the exacerbated 
antimicrobial response occurring in  IL-1R8-deficient mice that 
favored pathogen colonization. Thus, IL-1R8-mediated regulation 
of IECs is responsible for the inhibition of a strong antimicrobial 
response that would otherwise lead to a rapid depletion of the 
commensal microbiota, during intestinal infection. In turn, the 
absence of competing microflora would favor the colonization by 
bacterial pathogens (69).
These studies indicate that IL-1R8 plays a crucial role in 
favoring the maintenance of a delicate equilibrium between the 
protective immune response against infections and the develop-
ment of detrimental inflammation and host injury. The activity of 
IL-1R8 is therefore strictly dependent on the context and several 
lines of evidence suggest that during homeostasis the constitutive 
expression of IL-1R8 protects against inappropriate responses, 
whereas its downregulation during acute inflammatory stimula-
tion enhances the effectiveness (and pathogenic potential) of 
antibacterial host defense.
ROLe OF iL-1R8 iN 
AUTOiMMUNiTY AND ALLeRGY
The interest in studying IL-1R8 involvement in autoimmunity 
arises from the fact that ILRs and TLRs are key players in the 
pathogenic mechanisms of autoimmune disorders (Figure  4). 
In particular, IL-1 regulates the differentiation and function of 
Th17 cells, which are involved in inflammatory diseases such 
as rheumatoid arthritis (RA), multiple sclerosis, psoriasis, and 
inflammatory bowel disease (IBD) (70). IL-33 is a driver of 
type 2 inflammatory responses and is implicated in allergy and 
asthma (71).
Gulen et  al. recently showed that IL-1R8 was induced dur-
ing Th17 cell polarization and that it controlled Th17 cell 
differentiation, expansion, and effector functions through 
the direct  inhibition of IL-1 signaling in T cells. An increased 
phosphorylation rate of JNK, mTOR, and 4EBP1 was observed 
in IL-1R8-deficient T cells, upon stimulation with IL-1. In 
particular, IL-1-induced mTOR pathway was critical for the 
IL-1R8-mediated modulation of Th17 response. Thus, IL-1R8 
emerged as a key regulator of IL-1 activity in Th17 cells, and it 
was also observed to be involved in the Th17-mediated develop-
ment of central nervous system (CNS) autoimmune disorders. 
Indeed, IL-1R8-deficient mice revealed higher susceptibility to 
experimental autoimmune encephalomyelitis (EAE), due to an 
increased Th17 infiltrate in the CNS and enhanced Th17 polariza-
tion and pathogenic functions (61).
Toll-like receptors and ILRs are involved in the pathogenesis 
of RA (72–74). IL-1R8 was shown to suppress the spontaneous 
release of cytokines in human RA synovial cells in vitro, suggest-
ing its involvement in the modulation of chronic inflammation in 
RA. In vivo experiments supported this evidence, since IL-1R8-
deficient mice developed a more severe disease in both zymosan-
induced arthritis and collagen antibody-induced arthritis models, 
which was associated with increased cellular infiltration into the 
affected joints. IL-1Ra treatment reduced the susceptibility of 
IL-1R8-deficient mice in zymosan-induced arthritis, suggesting 
that IL-1 played a central role in this model. However, the pheno-
type of IL-1R8-deficient mice was not completely rescued by the 
treatment, possibly because other TLR (e.g., TLR2) or ILR ligands 
are implicated in zymosan-induced arthritis pathogenesis (74). 
In agreement with this study, IL-1R8 expression was reduced in 
peripheral blood of patients with psoriatic arthritis, compared 
with healthy donors (36). Moreover, IL-1R8 deficiency caused 
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enhanced susceptibility to psoriasis, associated with increased 
infiltration and activation of γδ T cells, in both Aldara- and 
rIL-23-induced psoriasis models. Interestingly, IL-R8 directly 
modulated IL-1-driven IL-17A expression by γδ T cells in vitro 
and in  vivo, and IL-17A depletion abolished the phenotype 
observed in IL-1R8-deficient mice (75).
Increasing evidences implicated IL-1R8 in the pathogenesis of 
systemic lupus erythematosus. Indeed, altered TLR signaling in 
DCs and B cells is one of the driving mechanisms of this autoim-
mune disorder. In particular, immune complexes containing the 
lupus autoantigen U1snRNP or nucleosomes activate DCs and 
autoreactive B cells via TLR7 and TLR9, respectively (76, 77). In 
the mouse, IL-1R8 deficiency alone did not induce autoimmunity 
against DNA. However, IL-1R8 deficiency in C57BL/6lpr/lpr mice, 
which develop delayed autoimmunity due to impaired Fas-
induced apoptosis of autoreactive B and T cells, caused increased 
activation of DCs and B cells and production of pro-inflammatory 
cytokines (CCL2, IL-6, and IL-12p40) and B cell antiapoptotic 
mediators (Baff/BlyS and Bcl-2). Moreover, IL-1R8 regulated B 
cell proliferation, upon exposure to RNA and DNA immune com-
plexes or other TLR agonists. IL-1R8-deficient C57BL/6lpr/lpr mice 
also displayed and increased production of autoantibodies (anti-
dsDNAIgG, anti-nucleosome, anti-Sm antigen, anti-snRNP, and 
rheumatoid factor) and presented a massive lymphoproliferative 
disorder, associated with enhanced autoimmune lung disease, 
lupus nephritis, and hypergammaglobulinemia, compared with 
IL-1R8-competent C57BL/6lpr/lpr controls (78). In line with this, 
IL-1R8 was also protective in a model of hydrocarbon oil-induced 
lupus, in which it modulated TLR7-mediated activation of DCs 
and expansion of autoreactive lymphocyte clones. IL-1R8 is 
therefore involved in the regulation of DC and B cell activation, 
by preventing exacerbated autoimmune reactions, lymphoprolif-
eration, and tissue damage in SLE (79). The data in the mouse 
were supported by recent analysis of IL-1R8 involvement in SLE 
in human. A case study of a cohort of SLE patients revealed a 
reduced frequency of IL-1R8+ CD4+ T cells in the peripheral blood 
of SLE patients compared with healthy individuals. Moreover, the 
frequency of IL-1R8+ CD4+ T cells was further reduced in SLE 
patients with nephritis, compared with those without nephritis 
(80). Zhu et al. showed that B cells from SLE patients displayed an 
upregulation of TLR7 and TLR9 compared with healthy controls, 
but the response to corresponding ligands was normal or even 
reduced. The authors suggested that this could be explained by 
the enhanced IL-1R8 expression in SLE B cells, even though the 
pathological significance of IL-1R8 increase in this context is still 
unclear (81). A genetic analysis of allelic variants of the IL-1R8 
gene in a large European-descent population showed no correla-
tion between IL-1R8 polymorphisms and SLE, but the analysis 
was restricted to a single missense SNP (rs3210908) (82). More 
recently, another genetic variant of IL-1R8 (rs7396562) was iden-
tified, and it was demonstrated to correlate with the susceptibility 
to SLE, in a Chinese population (83).
IL-33 signaling is a key driver of type 2 immunity, which 
favors protective immune responses in parasite infections and 
tissue repair but is also involved in pathological conditions, such 
as asthma, allergy, and eosinophilia (84). IL-33 receptor (IL-1R4/
ST2) affects innate and adaptive lymphoid cells (ILCs and Th2), 
inducing the production of type 2 cytokines (IL-4, IL-5, IL-13), 
and can be targeted by IL-1R8. Indeed, IL-1R8 inhibits IL-33-
mediated signaling in Th2 cells, controlling the production of type 
2 cytokines in vitro and in vivo (45). IL-1R8-deficient mice were 
shown to be hyper responsive to IL-33, in terms of lung inflamma-
tion, splenomegaly, and increased serum levels of IL-5 and IL-13 
(45). Moreover, in a model of allergic pulmonary inflammation 
induced by OVA, IL-1R8 deficiency was associated with increased 
leukocyte lung infiltration, IL-5 and IL-4 levels, and OVA-specific 
IgE induction, due to an exacerbated Th2 response (45). These 
results indicate that IL-1R8 serves as a negative feedback control 
in Th2 polarization and restimulation, thus controlling allergic 
inflammatory responses. However, a genetic study performed on 
a cohort of Japanese asthma patients revealed that none of the 
alleles or haplotypes of IL-1R8 identified were associated with 
asthma susceptibility or asthma-related conditions (85).
These data demonstrate the relevance of the control mediated 
by IL-1R8 on T and B lymphocytes and on antigen-presenting 
cells in the development of autoimmune and allergic diseases.
ROLe OF iL-1R8 iN KiDNeY STeRiLe 
iNFLAMMATiON
IL-1R8 is expressed at high levels in the kidney, in particular, 
by tubular epithelial cells and immune cells such as DCs and 
macrophages. Immunohistochemical analysis revealed extensive 
IL-1R8 positivity in the majority of tubular epithelial cells of the 
renal cortex, showing a predominant expression at the apical side 
of renal proximal tubules (29). IL-1R8 was shown to be a key 
player in sterile kidney diseases, by regulating TLR activation by 
nucleosomes and DAMPs, released during ischemic cell necrosis 
and associated with pathological conditions, such as lupus 
nephritis, postischemic acute renal failure, or kidney transplanta-
tion (78, 79, 86, 87) (Figure 4).
In a postischemic renal failure model, IL-1R8 deficiency was 
associated with increased renal injury, due to a massive activation 
of myeloid cells, increased intrarenal cytokine and chemokine 
production and increased leukocyte recruitment. In this model 
of sterile inflammation, DAMPs activate immune cells, in 
particular, neutrophils and macrophages, mainly via TLR4 and 
TLR2. In a model of renal ischemia/reperfusion, bone marrow 
chimeric mice demonstrated a major role of IL-1R8 in the 
hematopoietic compartment, since Il1r8+/+ animals transplanted 
with Il1r8−/− hematopoietic cells reproduced the phenotype of 
IL-1R8-deficient mice (86). In line with this, in a mouse model 
of fully mismatched kidney allotransplantation, IL-1R8-deficient 
grafts were less tolerated compared with control grafts, leading 
to acute rejection. Moreover, IL-1R8 deficiency was associated 
with an enhanced ILR- and TLR-driven posttransplant kidney 
inflammatory response, in particular, due to increased neutrophil 
and macrophage infiltrate and higher expression of TNFα and 
chemokines. An amplified adaptive response was also observed 
in IL-1R8-deficient mice, in which expansion and maturation 
of DCs was enhanced and the immune response against donor 
antigens was exacerbated. The higher allostimulatory activity of 
DCs may possibly explain the increased frequency of reactive T 
cells and reduced Treg development in absence of IL-1R8. Thus, 
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IL-1R8 plays a key role in the regulation of the allogeneic immune 
response in situ and is involved in graft survival (87).
In case of renal fibrosis induced by unilateral ureteral obstruc-
tion (UUO), IL-1R8 deficiency did not modulate the renal pathol-
ogy. Indeed, IL-1R8-deficient mice did not show any difference 
compared with controls in this model, in terms of mRNA tran-
script of pro-inflammatory and profibrotic mediators, leukocyte 
recruitment, and renal injury (88). These data are in line with the 
evidence that TLR2, TLR9, and MyD88 signaling are not involved 
in the pathogenesis of postobstructive renal fibrosis (89).
ROLe OF iL-1R8 iN BRAiN 
iNFLAMMATiON
IL-1R8 is expressed in the brain by neurons, microglia, and 
astrocytes, and it was shown to be involved in the regulation of 
LPS responsiveness in the brain (16, 33, 90) (Figure 4). Indeed, 
IL-1R8 deficiency was associated with a massive LPS-induced 
inflammation in the brain. In response to LPS, IL-1R8 negatively 
regulated CD40, ICAM, and cytokine (IL-6 and TNFα) mRNA 
expression in microglial cells and cytokine production in hip-
pocampal tissue. This is in line with an increased hippocampal 
expression of CD14 and TLR4, and NFκB activation in IL-1R8-
deficient mice (91).
In addition, it has been observed that cognitive and synaptic 
functions, such as novel object recognition, spatial reference 
memory, and long-term potentiation (LTP), were impaired in 
IL-1R8-deficient mice, in absence of any external stimulus. This 
was associated with a higher expression of IL-1R1 and TLR4 and 
an enhanced activation of IL-1R1 and TLR4 downstream sign-
aling molecules (IRAK1, c-Jun, JNK, and NFκB) (92). Indeed, 
treatment with IL-1Ra and anti-TLR4 antibody and the inhibition 
of JNK and NFκB rescued the deficit in LTP in IL-1R8-deficient 
animals, suggesting a central role of IL-1R1 and TLR4 signaling 
in this model. IL-1α and high mobility group box 1 (HMGB1), 
which activate IL-1R1 and TLR4, respectively, were proposed to 
play a central role in the phenotype observed and the expression 
levels of both molecules were increased in IL-1R8-deficient mice. 
These findings revealed a key role of IL-1R8 in modulating the 
inflammatory response associated with synaptic and cognitive 
decline and identified IL-1α and HMGB-1 as central mediators 
in this process (92). Moreover, IL-1R6 antagonist (IL-36Ra) 
inhibits the IL-1- and LPS-induced inflammatory response in 
glial cells, and this effect was absent in mixed glia prepared from 
IL-1R8-deficient mice, suggesting the involvement of IL-1R8 in 
the anti-inflammatory activity of IL-36Ra, possibly mediated 
through the production of IL-4 (16). Finally, a recent study 
showed that IL-1R8 acted as a negative regulator of β-amyloid 
(Aβ) peptide-induced TLR2 signaling in the brain. Aβ is the main 
component of neuritic plaques in Alzheimer’s disease (AD) and 
the primary mediator of the AD-associated neuroinflammation 
(49). The response to the TLR2 agonist (Pam3Cys4) was increased 
in glial cells from IL-1R8-deficient mice and Aβ-induced inflam-
mation in the brain was enhanced in IL-1R8-deficient mice, in 
terms of cytokine production (IL-6 and TNF-α). In vitro experi-
ments demonstrated that Aβ treatment increased the expression 
of TLR2 and decreased the expression of IL-1R8 in microglia 
and this was mimicked by the treatment with the TLR2 agonist 
Pam3Cys4. Anti-TLR2 treatment of microglia attenuated the 
inflammatory response and the impairment in LTP, both induced 
by Aβ, confirming the central role of TLR2 in the Aβ-induced 
neuroinflammation. Interestingly, TLR2 neutralization also led to 
an increase of IL-1R8 mRNA (49). These findings highlighted the 
key role of IL-1R8 in the modulation of TLR2-induced inflam-
mation in the brain and its relevance in a potential therapeutic 
approach targeting TLR2 in AD-related pathology.
ROLe OF iL-1R8 iN iNTeSTiNAL 
iNFLAMMATiON AND iNTeSTiNAL 
CANCeR
IL-1R8 was demonstrated to be a key regulator of intestinal 
homeostasis (Figure 4). IECs are intrinsically hyporesponsive to 
bacterial products, thus not only preventing exaggerate inflam-
matory responses against the commensal flora but also limiting 
the enteric host defense (56). On the other hand, gut microflora-
mediated activation of ILRs and TLRs provides the survival 
signals for IECs and this pathway is targeted by IL-1R8, which 
is therefore involved in controlling proliferation and survival in 
colon crypts (93). IL-1R8-deficient mice displayed constitutive 
NFκB and JNK activation and increased expression of Cyclin D1 
and Bcl-xL. The effect was further enhanced upon treatment with 
IL-1 or LPS, and it was dependent on the commensal flora, since 
microbiota depletion rescued the phenotype (93). This pheno-
type in healthy mice was not confirmed by other studies (56, 94), 
probably because of the animal house-dependent variation of the 
microflora. The relevance of IL-1R8 expression in IEC in terms 
of response to intestinal infections and control of commensal 
microbiota has been described above.
In dextran sodium sulfate (DSS)-induced colitis, IL-1R8 
deficiency is associated with an exacerbated intestinal inflam-
mation, in terms of weight loss, intestinal bleeding, local tissue 
damage, and a reduced survival. This correlates with an increased 
leukocyte infiltration in the intestine and higher level of pro-
inflammatory cytokines (TNFα, IL-6, IL-1β, IL-12p40, IL-17), 
chemokines (CXCL1, CCL2), and prostaglandins. Experiments 
with bone marrow chimeric mice demonstrated that the regula-
tory function exerted by IL-1R8 occurs in epithelial cells, in both 
DSS- and enteric pathogen-induced colitis (56, 93).
Epidemiological studies have shown that chronic inflamma-
tion, both dependent on infectious agents or not, can increase the 
risk of cancer. The hallmarks of cancer-related inflammation are 
comparable to those observed in chronic inflammatory condi-
tions: inflammatory cells and mediators are present in the tumor 
tissue, and they are implicated in tissue repair, remodeling, and 
angiogenesis. This “smoldering inflammation” occurs even in 
tumors that are not directly caused by an inflammatory trigger. 
Cancer-related inflammation depends on two possible pathways: 
an intrinsic pathway, driven by oncogenic mutations that cause 
both neoplasia and inflammation, or an extrinsic pathway, driven 
by inflammatory conditions that favor tumor development (e.g., 
colitis-associated intestinal cancer) (95–98). Several studies have 
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revealed a crucial role of ILR and TLR signaling in this context, in 
which NFκB is one of the key orchestrators, and that IL-1R8 plays 
a protective role in the pathogenesis of cancer-related inflamma-
tion in different murine models of colon cancer (98). IL-1R8 was 
studied in a model of CAC, induced by the treatment with the 
procarcinogen azoxymethane (AOM), followed by DSS, which 
favors chronic inflammation (93, 94). This model mimics intes-
tinal cancer that develops in chronic IBD patients, in particular, 
ulcerative colitis patients. In the AOM–DSS CAC model, IL-1R8 
deficiency was associated with exacerbated inflammation in the 
intestine, leading to increased susceptibility to cancer develop-
ment, in terms of number, size, and severity of lesions. IL-1R8 
negatively regulated intestinal permeability, in situ production of 
pro-inflammatory cytokines and chemokines and prostaglandin 
E2, and the expression of NFκB-induced genes involved in cell 
survival and proliferation (Bcl-xL and Cyclin D1) (93, 94). In this 
context, chemokines favored cancer progression, influencing the 
extent and type of leukocyte infiltrate (e.g., recruiting Th2 and 
Treg cells) and driving tumor cell and endothelial cell growth 
and migration (99, 100). Moreover, increased levels of IL-10 and 
TGF-β were observed in tumors of IL-1R8-deficient mice, reflect-
ing an immunosuppressive microenvironment that inhibited T 
cell-dependent antitumoral immunity (100). The expression 
of IL-6, which promotes cancer growth, was also increased in 
the intestine of IL-1R8-deficient mice (101, 102). IL-1R8 over-
expression in gut epithelial cells abolished the susceptibility of 
IL-1R8-deficient mice to CAC development, suggesting that the 
regulatory activity of IL-1R8 in IECs plays a central role in this 
model (93). Since commensal microflora-derived stimuli are nec-
essary for the homeostasis of colon epithelium and are involved in 
colitis-associated carcinogenesis, IL-1R8 regulation may be pos-
sibly dependent on its direct modulation of microbiota-activated 
TLRs (103). However, IL-1R8-mediated targeting of other TLR- 
and ILR-related pathways cannot be excluded in this model.
IL-1R8 involvement in colon cancer was also investigated in the 
genetic Apcmin/+ model, in which tumor initiation is caused by loss 
of heterozygosity (LOH) of the tumor suppressor Apc and which 
mimics the familial adenomatous polyposis syndrome (104). In 
Apcmin/+ mice, IL-1R8 deficiency led to an increased susceptibility 
to cancer development, due to a more sustained activation of the 
Akt/mTOR pathway, which plays a crucial role in tumor initiation 
(105). In agreement with the CAC model, commensal bacterial 
played a pivotal role in colonic tumorigenesis, suggesting that 
IL-1R8 regulation might occur through the inhibition of TLR 
signaling, even if mTOR enhanced activation was also observed 
upon stimulation of epithelial cells with IL-1. Thus, IL-1R8 exerts 
an antitumoral activity by suppressing IL-1- and TLR-induced 
mTOR-mediated cell cycle progression and consequent genetic 
instability (62).
A recent study has investigated the role of IL-1R8 in human 
colorectal cancer, demonstrating that colon tumors express 
lower level of IL-1R8 compared with healthy tissues and that 
IL-1R8 is frequently inactivated in human colorectal cancer 
(32). Indeed, Zhao et al. identified a dominant-negative isoform 
of IL-1R8 (IL-1R8ΔE8) and RNA sequencing data demonstrated 
that the expression level of this isoform increased in human 
colon cancer, compared with healthy tissue. The IL-1R8ΔE8 
isoform originated from a transcript that lacks the exon 8 of the 
gene and exhibited compromised integrity of the TIR domain, 
increased retention in the cytoplasm, and reduced N-linked 
glycosylation. The cytoplasmic retention caused a decrease in 
the cell surface expression of IL-1R8 and a consequent loss of its 
inhibitory activity. Moreover, IL-1R8ΔE8 isoform was shown to be 
able to interact with full-length IL-1R8, acting as an antagonist 
of IL-1R8 and thus suppressing its function. To investigate the 
mechanism responsible for IL-1R8ΔE8 isoform synthesis in tumor 
cells, sequence analysis were performed and predicted that exon 
8 would be intrinsically a “weak” exon, with high probability of 
exclusion. Exon 8 also displayed a binding site for CTCF, a factor 
that favors the inclusion of weak exons, and since the binding 
can be reduced by methylation, hypermethylation was proposed 
to be the strategy followed by cancer cells that leads to IL-1R8ΔE8 
isoform expression. Indeed, treatment with decitabine, a methyl-
transferase inhibitor, reduced IL-1R8ΔE8 isoform expression. To 
model the impact of IL-1R8ΔE8 isoform in colon carcinogenesis in 
the mouse, gut epithelium-specific IL-1R8 transgenic mice were 
generated, expressing a mutant form of IL-1R8 (IL-1R8N85/101S) 
that mimics IL-1R8ΔE8 isoform or wild-type IL-1R8 as a control. 
In both AOM and AOM–DSS models, the presence of wild-type 
IL-1R8 in IECs protected the mice from the development of colon 
cancer. On the contrary, mice expressing IL-1R8N85/101S isoform 
had the same phenotype as IL-1R8-deficient mice, suggesting 
that complex glycan modifications and cell surface expression are 
necessary for IL-1R8 functional activity in vivo (32). Thus, IL-1R8 
alternative splicing is an escape mechanism adopted by tumor 
cells to inactivate IL-1R8 through the generation of a dominant-
negative isoform.
ROLe OF iL-1R8 iN CHRONiC 
LYMPHOCYTiC LeUKeMiA
Both genetic defects and microenvironment stimuli contribute to 
chronic lymphocytic leukemia (CLL) development and progres-
sion. Moreover, factors originating from the microenvironment 
are involved in the selection and expansion of the malignant 
clone (106, 107). Human malignant B cells expressed lower 
levels of IL-1R8 mRNA than normal B cells, and accordingly, 
in the well-established transgenic mouse model of CLL (TCL1), 
CD19+ B cells expressed lower levels of IL-1R8 mRNA transcript, 
compared with controls (107–110). IL-1R8 deficiency did not 
affect B cell compartment in healthy mice, whereas it correlated 
with an earlier and more severe appearance of monoclonal B cell 
expansion and a reduced mouse life span in TCL1 transgenic 
mice, mimicking the aggressive variant of human CLL (110). 
These findings revealed IL-1R8 inhibitory role in CLL initiation 
and progression, even though the molecular mechanism is still 
unclear (Figure 4). Endogenous TLR or ILR ligands are known 
to be involved in CLL and may be candidate targets of IL-1R8.
CONCLUDiNG ReMARKS
It is well established that IL-1R8 acts as negative regulator of ILR 
and TLR signaling, which are key pathways involved in inflam-
mation and immunity. Early studies are consistent with the 
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fact that IL-1R8 is a conserved and widely expressed molecule 
that plays a key role in the modulation of inflammation, tissue 
damage, and host defense against infections, autoimmunity, and 
cancer. Its mechanism of action is probably dependent on the 
interaction with TIR domain containing-signaling molecules, 
preventing the signalosome formation and activation. Although 
IL-1R8 was considered an orphan receptor, IL-36Ra has been 
proposed as brain-specific IL-1R8 ligand. Recently, IL-1R8 has 
been shown to act as a coreceptor for IL-37–IL-1R5/IL-18Ra 
and to be required for the anti-inflammatory activity of IL-37 
(11, 51, 52). Indeed, IL-37 needs IL-1R8 to trigger a rapid 
anti-inflammatory program, revealing a novel role for IL-1R8. 
In addition to its regulatory activity, IL-1R8 therefore emerges 
as a coreceptor molecule, which able to boost IL-37-mediated 
signaling. Since IL-37 ameliorates insulin resistance and obesity-
induced inflammation (54), it will be important to address 
whether IL-1R8 is involved in these contexts, preserving glucose 
tolerance and insulin sensitivity and reducing inflammation in 
the adipose tissue.
IL-1R8 regulates the metabolism, activation and polarization 
of several innate and adaptive immune cell types, as well as of 
non-hematopoietic cells. Thus, it plays a non-redundant role in 
the regulation of both pathogen-induced and sterile inflamma-
tion, managing the delicate equilibrium between host defense 
and detrimental inflammation.
The IL-1 system and TLR ligands affect all cells of the 
immune system, as well as epithelial, endothelial, and stromal 
cells. Since IL-1R8 is expressed by most cell types, but its 
functional characterization is still incomplete, future studies will 
be  important to identify the peculiar role of IL-1R8 in the regula-
tion of ILR- and TLR-dependent activation in specific cell types.
The involvement of IL-1R8 in human pathologies needs to be 
further investigated, since it could emerge as a potential target 
in several inflammatory contexts. Results showing that IL-1R8 
inactivation is an escape mechanism adopted by cancer cells in 
human colon cancer are of particular importance, since they rep-
resent the first strong genetic evidence of the relevance of IL-1R8 
in human disease. Further analysis of IL-1R8 polymorphisms and 
epigenetic regulations of IL-1R8 gene represent important future 
directions to gain a more precise view of IL-1R8 involvement in 
human diseases.
Given the well-established role of IL-1R8 as a key anti-inflam-
matory molecule in a broad spectrum of contexts, its targeting 
holds promise of innovative therapies in several pathological 
conditions.
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